



Company Overview

CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

CohBar Reports First Quarter 2019 Financial Results and Business Update May 7 2019, 4:03 PM EDT

CohBar Appoints Steven B. Engle as Chief Executive Officer May 7 2019, 9:00 AM EDT

CohBar to Resume its Phase 1a/1b Clinical Trial May 3 2019, 9:00 AM EDT

Stock Overview

| | |
|------------|-------------------|
| Symbol | CWBR |
| Exchange | Nasdaq |
| Market Cap | 81.51m |
| Last Price | \$2.04 |
| 52-Week | \$2.05 - \$10.789 |

05/17/2019 04:00 PM EDT

Investor Relations

Jon Stern, COO
Investor Relations
T: (650) 446-7888
jon.stern@cohbar.com

Management Team

Steven B. Engle, M.S.
Chief Executive Officer

Kenneth C. Cundy, Ph.D.
Chief Scientific Officer

Jeffrey F. Biunno, CPA, MBA
Chief Financial Officer, Secretary and Treasurer

Jon L. Stern, MBA
Chief Operating Officer, Director

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.